143 related articles for article (PubMed ID: 31807857)
1. Systemic mastocytosis with associated BCRABL1-negative atypical chronic myeloid leukemia.
Caocci G; Greco M; Frau V; Asproni R; Piras G; Palmas A; Casula P; La Nasa G
Ann Hematol; 2020 Feb; 99(2):363-365. PubMed ID: 31807857
[No Abstract] [Full Text] [Related]
2. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.
Horny HP; Sotlar K; Sperr WR; Valent P
J Clin Pathol; 2004 Jun; 57(6):604-8. PubMed ID: 15166264
[TBL] [Abstract][Full Text] [Related]
3. Cytology of systemic mastocytosis.
Bain BJ; Marks AJ
Am J Hematol; 2009 Dec; 84(12):842. PubMed ID: 19787646
[No Abstract] [Full Text] [Related]
4. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: a case review.
Ustun C; Savage NM; Gotlib J; Bhalla K; Manaloor E; George TI
Am J Hematol; 2012 Feb; 87(2):191-3. PubMed ID: 22081475
[No Abstract] [Full Text] [Related]
5. Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia.
Ustun C; Williams S; Skendzel S; Kodal B; Arock M; Gotlib J; Vallera DA; Cooley S; Felices M; Weisdorf D; Miller J
Am J Hematol; 2017 May; 92(5):E66-E68. PubMed ID: 28187525
[No Abstract] [Full Text] [Related]
6. Systemic mastocytosis associated with acute myeloid leukaemia.
Kim MJ; Kim MK; Kim YK; Gu MJ
Pathology; 2017 Oct; 49(6):652-654. PubMed ID: 28826833
[No Abstract] [Full Text] [Related]
7. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.
Yoshida C; Takeuchi M; Tsuchiyama J; Sadahira Y
Intern Med; 2009; 48(22):1973-8. PubMed ID: 19915299
[TBL] [Abstract][Full Text] [Related]
8. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
9. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge.
Arredondo AR; Gotlib J; Shier L; Medeiros B; Wong K; Cherry A; Corless C; Arber DA; Valent P; George TI
Am J Hematol; 2010 Aug; 85(8):600-6. PubMed ID: 20658589
[No Abstract] [Full Text] [Related]
10. Aggressive systemic mastocytosis mimicking sclerosing cholangitis.
Marbello L; Anghilieri M; Nosari A; Minola E; Cairoli R; Ricci F; Morra E
Haematologica; 2004 Sep; 89(9):ECR35. PubMed ID: 15377487
[TBL] [Abstract][Full Text] [Related]
11. From the observation of atypical cells on blood smear to the diagnosis of mast cell leukemia: a case report in a 79 year old woman consulting for anemia.
Decker J; Meyer S; Latger-Cannard V; Visanica S; Loppinet E; Lesesve JF; Bénet B
Ann Biol Clin (Paris); 2017 Dec; 75(6):689-694. PubMed ID: 29043985
[TBL] [Abstract][Full Text] [Related]
12. Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease (SM-AHNMD) in an infant patient.
Kawakami T; Haga T; Soma Y; Nagae C; Kinoshita A
J Dermatol; 2014 Aug; 41(8):761-3. PubMed ID: 25099159
[No Abstract] [Full Text] [Related]
13. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
14. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
Schneeweiss M; Peter B; Bibi S; Eisenwort G; Smiljkovic D; Blatt K; Jawhar M; Berger D; Stefanzl G; Herndlhofer S; Greiner G; Hoermann G; Hadzijusufovic E; Gleixner KV; Bettelheim P; Geissler K; Sperr WR; Reiter A; Arock M; Valent P
Haematologica; 2018 May; 103(5):799-809. PubMed ID: 29439183
[TBL] [Abstract][Full Text] [Related]
15. Education and Imaging. Hepatobiliary and pancreatic: systemic mastocytosis with portal hypertension.
Wong D; Boyapati R; Lokan J; Angus P
J Gastroenterol Hepatol; 2014 Aug; 29(8):1572. PubMed ID: 25073633
[No Abstract] [Full Text] [Related]
16. Mastocytosis and related disorders.
Chiu A; Orazi A
Semin Diagn Pathol; 2012 Feb; 29(1):19-30. PubMed ID: 22372203
[TBL] [Abstract][Full Text] [Related]
17. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
[TBL] [Abstract][Full Text] [Related]
18. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone.
Pullarkat V; Bedell V; Kim Y; Bhatia R; Nakamura R; Forman S; Sun J; Senitzer D; Slovak ML
Leuk Res; 2007 Feb; 31(2):261-5. PubMed ID: 16876862
[TBL] [Abstract][Full Text] [Related]
19. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
20. A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases.
Grifoni FI; Sciumè M; Pravettoni V; Ulivieri FM; Muratori S; Fracchiolla NS; Tagliaferri E; Gianelli U; Migliorini AC; Cro L; Pacilli A; Mannelli F; Baldini L
Hematol Oncol; 2019 Apr; 37(2):205-211. PubMed ID: 30849188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
